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Background: Embelin, a quinone derivative, is found in the fruits of Embelia ribes Burm (Myrsinaceae). It has been
shown to have a variety of therapeutic potentials including anthelmintic, anti-tumor, anti-diabetic, anti-bacterial
and anti-inflammation. Inflammation is an immunological response to external harmful stimuli and is regulated
by an endogenous pyrogen and pleiotropic pro-inflammatory cytokine, tumor necrosis factor alpha (TNF-α). TNF-α
production has been implicated in a variety of other human pathologies including neurodegeneration and cancer.
Several studies have shown that the anti-inflammatory activity of embelin is mediated by reduction in TNF-α. The
latter is synthesized as a membrane anchored protein (pro-TNF-α); the soluble component of pro-TNF-α is then
released into the extracellular space by the action of a protease called TNF-α converting enzyme (TACE). TACE,
hence, has been proposed as a therapeutic target for inflammation and cancer.
Methods: We used molecular docking and experimental approaches to investigate the docking potential and
molecular effects of embelin to TACE and human cancer cell characteristics, respectively.
Results: We demonstrate that embelin is a potential inhibitor of TACE. Furthermore, in vitro studies revealed that it
inhibits malignant properties of cancer cells through inactivation of metastatic signaling molecules including MMPs,
VEGF and hnRNP-K in breast cancer cells.
Conclusion: Based on the molecular dynamics and experimental data, embelin is proposed as a natural
anti-inflammatory and anticancer drug.
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Inflammation is an immunological process induced by
vascular tissues of the body in response to certain external
stimuli. It involves various chemical mediators called cyto-
kines that help in the healing of infected tissues. Even
though it is a protective response within the body, it may
sometimes result in chronic and life threatening effects
like rheumatoid arthritis, hay fever, neurodegenerative
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unless otherwise stated.considered to be a potential therapeutic strategy for the
treatment of inflammatory disorders. Many different
anti-cytokine approaches including, cytokine neutralization
by soluble receptors or activation of anti-inflammatory
pathways using monoclonal antibodies are in practice [2].
Tumor necrosis factor alpha (TNF-α), a major immuno-
modulator and pro-inflammatory cytokine, plays a crucial
role in various immunological disorders and inflammations
in skin. TNF-α receptors are found in almost all cell types
and are known to be involved in several physiological
processes. It also leads to multiple inflammatory reactions
by inducing the production of secondary cytokines [3].
TNF-α is synthesized as a 223 amino acid long membrane-
anchored precursor protein (pro-TNF-α) of 26-kDa. The
17-kDa soluble component of TNF-α is released into thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Val-77 bond [4,5]. Several different proteases have been
found to be involved in this process. Out of these, TNF- α
converting enzyme (TACE), a metalloprotease, is consid-
ered to be the most efficient enzyme for the proteolytic
processing of pro-TNF-α [6]. Since the enzyme plays an
important role in converting TNF-α to its soluble form,
counteracting the increase in TNF-α concentration in
inflammatory disorders by targeting TACE enzyme could
provide a potential therapeutic strategy to check inflam-
mation diseases. The role played by TNF-α in the patho-
physiology of inflammatory diseases has allowed the
development of many new anti-cytokine synthetic drugs
that can interfere with excess TNF-α. However, in a study
conducted by World Health Organization (WHO), these
drugs were associated with drug-related or drug-induced
toxic effects, such as, gastric irritation, ulceration, bleed-
ing, renal failure, interstitial nephritis, hepatic failure,
headache, thrombocytopenia, hemolytic anemia, asthma
exacerbation, skin rashes, angioedema and pruritus [1].
Because of these potential side effects, natural products or
herbal drugs are regaining popularity and hence have
attracted research attention for solving their mechanism
of therapeutic action.
The fruit of Embelia ribes Burm (Myrsinaceae) (known
as false black pepper in English, Vidanda in Sanskrit
and Babrang in Hindi languages) has been in use to
treat a variety of gastrointestinal ailments, fever and
inflammatory diseases for thousands of years. The active
constituent is a quinone derivative, 3-undecyl 2,5-dihy-
droxy, 1,4-benzoquinone commonly known as embelin,
and is isolated from the berries of the plant [7]. It has been
shown to possess therapeutic activities like anthelmintic
[8], anti-tumor, analgesic [9], anti-inflammatory and
anti-diabetic [10], anti-bacterial [11], anticancer [12]
and anticonvulsant [13]. The molecular mechanism of
such activities of embelin is largely unknown. However, it
has been shown that embelin is an inhibitor of X-linked
anti-apoptotic protein and also blocks the nuclear factor-
kappa B (NF-κB) signaling pathways thus leading to the
downregulation of a variety of anti-apoptotic and meta-
static gene products [14]. It has also been shown to have
in vivo anti-inflammatory activity in both acute and choric
model of psoriasis or inflammatory skin diseases. It has
been reported to reduce TNF-α production in both
LPS- and TPA-induced inflammation [7]. In the present
study, we first performed molecular dynamic simulations
of TACE protein docked with embelin. Based on these
data, we investigated the inhibitory effect of embelin on
TACE and its downstream signaling involved in cancer
cell progression and metastasis. We demonstrate that the
embelin-treated human breast cancer cells have reduced
levels of TACE and TNF-α. Furthermore, they showed
inhibition in growth and cancerous properties includingcolony forming efficacy, migration and invasion that were
mediated by down regulation of MMP-2, MMP-9, VEGF
and hnRNP-K proteins.
Methods
Protein and ligand preparation
The crystal structure of TACE [PDB ID: 1BKC] was
obtained from Protein Data Bank (PDB) [15]. Before
docking, ligand present in the structure, obtained from
PDB, was deleted. The crystal structure was made clean by
removing water molecules. The energy of the protein mol-
ecule was minimized by Steepest Descent and Conjugate
Gradient method using Accelrys Discovery Studio, the
most comprehensive suite for modeling and simulation
solutions. The minimization process was carried out using
CHARMM force field. The protein was then prepared for
docking using Schrödinger’s protein preparation wizard
[16]. The protein preparation steps included assigning
correct bond orders, addition of hydrogens, creation of
disulphide bonds, conversion of selenomethionine to
methionine and capping of terminal residues. After the
preprocessing and preparation steps, the H-bonds were
further optimized.
The ligand molecule, embelin [CID: 3218] was retrieved
from NCBI – PubChem Compound Database. Ligand was
also prepared using Schrödinger’s LigPrep protocol. It
helps in the generation of all possible tautomeric, ionic
and stereochemical states of the ligands, followed by their
energy minimization. Figure 1A shows the 2D skeleton of
the ligand, embelin.
Prediction of active site
The identification of catalytic residues is a key step in
understanding the function of an enzyme. Although some
information was available about the active site of TACE
from its co-crystallized structure with its inhibitor [15],
the active site residue were predicted in silico to further
validate the available information. Q-site Finder web
server was used to predict the most probable active
cleft of TACE along with the amino acid residues lining
this functionally active site. It uses energy criteria in
order to predict the active binding cleft. It calculates the
van der Waals interactions of a methyl probe with protein
molecule. The probe sites with favorable energy are then
clustered based on their spatial proximities. The clusters
are ranked according to the total interaction energies, and
the cluster with maximum energy is ranked first [17].
Molecular docking
Glide docking module of Schrödinger [18,19] was used
to investigate the interactions between embelin and TACE.
A three dimensional grid was generated with center
around the critical residues of TACE, which involve Gly
348, Val 349, His 405, His 409 and His 415 (His residues
Figure 1 Docking of embelin to TACE. (A) Chemical structure of embelin. (B) Embelin docked into the active site of TACE. (C) Residues of
TACE involved in hydrogen bond (pink) and non-bonded (yellow) interactions with embelin.
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molecule). The size of the grid was 20 cubic Å. The
docking calculations were performed using the XP
(extra precision) mode of Glide. It performs systematic
search of conformational, orientation and positional space
of docked ligand, discarding unwanted conformations
using scoring followed by energy optimization. The con-
formations are further refined via Monte Carlo sampling
of pose conformations. The XP docking score of the
complex was coming out to be −9.06 indicating a high
binding affinity of the ligand with TACE. The molecular
interaction pattern was studied using the Ligplot pro-
gram [20]. All the docking runs were performed using
Intel(R) Core™ 2 Duo CPU, T5870@ 2.00GHz of hp origin,
1.99 GB of RAM.
Confirmation of docking by AutoDock and Sanjeevni
The docking results obtained from Glide were confirmed
using AutoDock Suite 4.0 [21] and ParDOCK [22]. For
Autodock, the protein molecule was prepared by adding
polar hydrogens for correct ionization and tautomeric
states of amino acid residues and non-polar hydrogens
were then merged-up. Gasteiger charges and rigid roots
were assigned to ligand and 13 bonds were made rotat-
able. The energy-scoring grid of 60 Å × 60 Å × 60 Å (x,
y, z) was prepared incorporating the key residues. The
default parameters of Lamarckian genetic algorithm
were used as a search protocol for finding the best con-
formation. To further verify the results, the docked com-
plex was also submitted to ParDOCK which follows
Monte Carlo docking protocol [22].
MD simulations in water
Desmond Molecular Dynamics System [23,24] with
Optimized Potential for Liquid Simulations [25,26] all
atom force field was used to study the dynamic stabil-
ity of the complex. At first, the complex obtained aftermolecular docking using Glide XP protocol was solvated
in a triclinic periodic box of TIP3 water and then neu-
tralized with appropriate number of counter-ions. The
distance between the walls of the box and the complex
was kept 10 Å to prevent the interaction of ligand bound
protein with its own periodic image. This prepared system
was then subjected to energy minimization up to a max-
imum of 3000 steps using a steepest decent method or
until a gradient threshold (25 kcal/mol/Å) was not
reached. The equilibrated system was then used to carry
out further MD simulations for 10 ns at a constant temp-
erature of 300 K and a constant pressure of 1 atm with a
time step of 2 fs. Smooth particle Mesh Edwald method
was used to calculate long distance electrostatic inter-
actions. A 9 Å cutoff radius was used for calculating
coloumbic short-range interactions. Frames of the trajec-
tory were captured after every 4.8 ps of the time interval.
Cell culture, treatments, viability and morphological
observations
Human breast cancer cell lines, MCF-7 and MDA-MB-
231, were obtained from JCRB (Japanese Collection of
Research Bio-resources) Cell Bank and cultured in DMEM
(Life Technologies, Carlsbad, CA, USA), supplemented
with 10% fetal bovine serum and antibiotics at 5% CO2
and 95% air in a humidified incubator. Mortalin overex-
pressing derivatives of MCF-7 and MDA-MB-231 cells
were generated by retroviral infections, as described
previously [27,28]. Embelin (Sigma-Alrich, Japan) stock
(10 mM in DMSO) was prepared and stored at −20°C.
Working concentrations were prepared in DMEM at
the time of treatments. Cells were cultured to 60-70%
confluency and then treated with embelin. For morpho-
logical observations, cells were plated in 6-well plates
and treated as indicated. Morphologies of control and
treated cells were recorded at 12, 24, 48, 72 and 96 h
post-treatments using a phase contrast microscope. Cell
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plates. Following incubation with embelin (15 μM)-sup-
plemented medium for 24–72 h, as indicated in the
results, cells were incubated with MTT (0.5 mg/ml) for
3 h followed by addition of DMSO (100 μl) to each well.
Absorbance was recorded at 550 nm using a multi-well
plate reader (Tecan, Switzerland). Data obtained from
three independent experiments were analyzed, and the
significances were calculated by t-test calculator (GraphPad
Software, Inc., CA).
Colony forming assays
Colony forming ability of cells was examined by plating
500 cells in a 6-well dish. After overnight incubation, the
cells were treated with a medium supplemented with
embelin. The dish was then left in an incubator for the
cells to develop colonies for the next 10–15 days, with a
regular change in media every alternate day. Once the
colonies were formed, they were fixed in methanol, stained
with 0.1% crystal violet, photographed and counted.
Wound scratch assay
In vitro cell migration ability of control and embelin-
treated cells was determined by wound scratch assay.
Cells were cultured in monolayer, followed by wounding
with a 200 μl pipette tip. Cells were washed with PBS
to remove off any debris, and then supplemented with
embelin containing medium. The time of scratching the
wound was designated as 0 h. Cells were allowed to
migrate into the wound. The migration ability was
recorded at 24 h using a phase contrast microscope at 10 ×
magnification and quantitated by using the Wimscratch
software (Wimasis Image Analysis, Germany).
In vitro chemotaxis assay
Cells (60-70% confluency) were washed with cold PBS,
trypsinized, and re-suspended in DMEM-supplemented
with 0.5% bovine serum albumin (Sigma) at a cell con-
centration of 5 × 104 cells/ml. Cells (2.5 × 104) were
plated in BioCoat™ Matrigel™ Invasion Chambers (8-mm
pore, BD Biosciences), in the presence or absence of
embelin, and the invasion assay was performed following
the manufacturer’s instructions. Cells that had invaded
through the matrigel and migrated through the membrane
were extracted with 10% acetic acid, and their absorbance
was measured at 590 nm using a Microplate Reader
(Tecan, Switzerland).
Immunoblotting
Cells, after the treatment with embelin, were harvested
and lysed by RIPA (RadioImmune Precipitation Assay)
Buffer (Thermo Fisher Scientific Inc., IL). 20 μg of protein
lysate from control and embelin-treated cells were resolved
on 10% SDS-polyacrylamide gels, and transferred to PVDFmembrane. The expression level of TACE, MMP-9, MMP-
2, VEGF proteins, in response to embelin treatment,
was determined by incubating the blots with their
specific antibodies followed by probing with respective
secondary antibodies. Membranes were probed with anti
β-actin antibody (Abcam, Cambridge, UK) as an internal
loading control. The pixel calculation of western blots
by actin normalization was done using ImageJ software
(NIH, MA).
TACE activity assay
Cells (5 × 104) were plated in 6-well plates. After the cells
had fully attached to the substratum, they were incubated
with embelin for 24 h, washed with PBS, lysed and their
TACE activity was measured following manufacturer’s
protocol (Sensolyte, Anaspec Inc., CA). A standard TACE
inhibitor, TAPI-0 (10 μM) (Peptides International Inc.,
Louisville, KY), was used as a control.
TNF-α ELISA
An ELISA assay for TNF-α was performed using a human
TNF-α ELISA kit (Abcam, Cambridge, UK). Briefly, Cells
were cultured overnight, followed by treatment with embe-
lin (15 μM) for 24 h. Cell supernatant was then harvested
and centrifuged to remove any cell debris. The resultant
supernatant was then used for ELISA following the manu-
facturer’s protocol.
RT-PCR
RNA was extracted from control and embelin-treated cells
using Qiagen RNeasy kit (Qiagen, Limburg, Netherlands).
RNA (2 μg) was reverse transcribed to cDNA using the
ThermoScript Reverse Transcriptase (Life Technologies)
following manufacturer’s protocol. PCR amplifications
were performed using equal amount of synthesized cDNA
with gene specific sense and antisense primer sets using
Phusion High-Fidelity DNA Polymerase (New England
Biolabs Inc., MA). PCR amplification conditions were set
as initial denaturation (95°C, 5 min) followed by 30 cycles
of amplification (95°C for 45 s, 60°C for 1 min and 72°C
for 45 s) with final annealing at 72°C for 10 min. Ampli-
fied products were resolved on 1% agarose gel, and were
visualized by ethidium bromide staining. Quantitation of
PCR products was performed with ImageJ and statistical
analysis was carried out using Student’s t test, wherein
p values scores ≤0.05 was considered significant. The
gene specific primer sequences used as follows: TNF-α:
5′-GGAGAAGGGTGA CCGACTCA-3′ (Sense) & 5′-
CTG CCC AGA CTC GGC AA-3′ (antisense); TGF-α
5′-CACACTCAGTTCTGCTTCCA-3′ (sense) & 5′-TCA-
GACCACTGTTTCTGAGTGGC-3′ (antisense); AREG
(Amphiregulin): 5′-GACCTCAATGACACCTACTCTGG-
3' (sense) & 5′-AAATATTCTTGCTGACATTTGC-3′
(antisense); Akt: 5'-ATGAGCGACGTGGCTATTGTGA
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ATG-3' (antisense); ERK-2: 5'-AAGGTGCCATGGAAC
AGGCTGT-3' (sense) & 5'-TCCTCTGAGCCCTTGTCC
TGAC-3' (antisense); ULBP-2: 5'-CAGAGCAACTGCGT
GACATT-3' (sense) & 5'CATGCCCATCAAGAAGTCC
T-3' (antisense); CD163: 5'-AGAGGCTGGGGACTGA
AAGAA-3' (sense) & 5' GCAGATAACTCCCGCATC
CTCCTT-3' (antisense), and GAPDH (internal control)
5′-ACCTGACCTGCCGTCTAGAA-3′ (sense) & 5′-TCC
ACCACCCTGTTGCTGTA-3′(antisense).
Immunofluorescence
For immunofluorescence study, cells were cultured on
coverslips placed in 12-well dish. After overnight incuba-
tion, cells were treated with embelin for 24 h, washed
with cold PBS and fixed with methanol: acetone (1:1) for
5 min. Fixed cells were washed twice with 1 X PBS,
permeabilized using 0.5% Triton X-100 in PBS for 10 min,
and blocked using 2% BSA in PBS for 15 min. Coverslips
containing cells were incubated with antibodies against
TACE, MMP-9, MMP-2, VEGF (Santa Cruz Biotechnology
Inc., Texas), hnRNP-K (Cell Signaling Technology Inc.,
MA) proteins for 2 h at room temperature, washed thrice
with 0.2% Triton X-100 in PBS followed by incubation with
Alexa Fluor conjugated secondary antibodies. After further
washings with 0.2% Triton X-100 in PBS, cells on cover-
slips were mounted and visualized under Carl Zeiss micro-
scope (Axiovert 200 M).
Results
Identification of the active catalytic cleft in TACE protein
The pre-processed structure of TACE was submitted to
Q-site Finder server. Based on the interactions of probe
with protein molecule it returned ten energetically favored
clusters. The individual probe sites relate most closely to
the favored high-affinity binding sites on the protein
surface and are the locations where a putative ligand
could bind and optimize its van der Waals interaction
energy [17]. The topmost site in the results obtained
had a volume of 571 cubic Å. It included approximately
27 residues, namely Gly 346, Thr 347, Leu 348, Gly
349, Leu 350, Ala 351, Asn 389, Tyr 390, Lys 392, Thr
393, Ile 394, Leu 395, Glu 398, Ala 399, Leu 401, Val
402, His 405, Glu 406, His 409, His 415, Tyr 433, Val
434, Met 435, Tyr 436, Pro 437, Ile 438, Ala 439, Val
440 and Ser 441. The grid generated while molecular
docking was made to cover all of these residues that
constituted the active site.
Flexible docking of embelin into the functional cavity
of TACE
A possible mode of action proposed here to substantiate
the role of embelin in reducing the levels of TNF-α in
inflammation is by interaction of ligand with the keyresidues of TNF-α converting enzyme (TACE). Chemical
structure of embelin is shown in Figure 1A. The Glide
XP score for binding of embelin to TACE was −9.06,
which indicated a high affinity of embelin for TACE pro-
tein. As shown in the Figure 1B, the ringed structure
forming the head of the ligand got buried into the active
pocket of TACE, while the long hydrophobic twisted tail
was also found to interact closely with the small groove
in the protein, as shown by the mesh representation.
The active cleft of TACE has catalytic zinc residing at its
center, penta-coordinated by three imidazole N2 atoms of
His 405, His 409 and His 415 [15]. The active center of
TACE has also been reported to possess remarkable simi-
larity with other zinc metalloproteases (MMPs) including
a conserved amino acid sequence-HExGHxxGxxH- [29].
This motif in TACE stretches from residue number 405 to
415. In general reaction mechanism, the zinc ion assumes
a quasi penta-coordinated state after dissociating from the
histidine residue of this conserved zinc-binding motif.
This change in state causes the polarization of oxygen
atom of the glutamic acid that lies close to the scissile
bond of the substrate, thereby acting as a reversible elec-
tron donor. This forms an oxyanion transition state. At
this stage, the water molecule acts on the dissociated scis-
sile bond and completes the hydroxylation of the substrate
[30]. The binding of embelin to TACE was characterized
by H-bonds formed with two of the critical residues
namely Leu 348 and Gly 349 as illustrated in Figure 1C.
Previous studies have reported that these two residues
play an important role in the catalytic activity of the pro-
tein [31]. The length of the H-bonds was 2.80 and 3.06 Å
respectively. Embelin was also found to form a coordinate
bond with the zinc atom. Many residues of this conserved
zinc-binding motif were seen to interact with the ligand.
These included His 405, Glu 406 (which acts as a general
base during catalysis), His 409 and His 415. Along with
these residues, Trp 312, Asp 313, Val 314, Asp 344, Met
345, Thr 347 and Pro 437 lining the inner surface of the
active site were also showing hydrophobic and van der
Waals interactions with the docked embelin.
Mimicking the in vivo conditions using molecular
dynamics simulations
It is important to study the protein ligand interaction in
dynamic motion. Desmond Molecular Dynamic System
was used for 10 ns simulation of the complex (Figure 2).
Figure 2A shows the RMSD of backbone of TACE protein
calculated in reference to the first frame over the entire
simulation trajectory. As observed from the RMSD graph,
the protein deviated up to 2 Å in first half of the simula-
tion run after which it acquired quite a stable state.
Figure 2D shows the change in the orientation of the
bound embelin with progression in the simulation time.
The ligand did not show significant variation in the
Figure 2 Kinetic of embelin docking to TACE. (A) Trajectory showing root mean square deviation in the conformation of TACE backbone
in reference to the docked complex over the entire simulation run. (B) Molecular interaction pattern between TACE and embelin after MD
simulations. (C) Difference in the binding pose of embelin before (red) and after (blue) MD simulation. (D) Changes observed in the docking
conformation of embelin during the simulations of 10 ns duration.
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structure was generated for this time period. The protein
backbone was also most stable in this interval of time as
depicted by the RMSD curve. The residues of TACE that
were involved in hydrogen bonding with the embelin
molecule were investigated using the average structure.
A total of 34 hydrogen bonds were formed during the
entire simulation run of 10 ns. The residue pairs with
high occupancy were the ones that persisted for more
than half of the run and hence were responsible for the
stable binding of embelin within the active site of TACE.
Table 1 lists all the H bonds with their occupancy.Figure 2B illustrates the binding pattern of embelin with
TACE in its dynamically stable conformation, represented
by the computed average representative structure. It
was observed that the two H bonds found subsequent
to docking persisted even after the 10 ns simulation
run with occupancy of 92.81 and 73.54%. Apart from
these bonds, 2 new H bonds of 2.65 and 3.05 Å were
formed involving Glu 406 and His 409 respectively. The
bond of 2.65 Å between Glu 406 and embelin had the
maximum occupancy, of 96.74%. Even though a bond
between Gly 346 and embelin also was observed with
occupancy of 43.43%, it did not appear in the structure
Table 1 List of residues pairs participating in hydrogen
bond formation during the entire MD simulation run
S. No. Donor Acceptor Occupancy (%)
1 Leu 348 (M) Embelin 92.81
2 Gly349 (M) Embelin 73.54
3 Gln406 (S) Embelin 96.74
4 Embelin Gly346(M) 43.43
5 Thr347 (S) Embelin 1.82
6 His405 (S) Embelin 3.79
7 Embelin Gly349 (M) 4.03
8 Val314 (M) Embelin 0.10
9 Embelin Val314 (M) 0.10
10 Embelin Thr347 (S) 1.87
11 Embelin Glh406 (S) 13.71
12 Embelin Pro437 (M) 21.33
13 Embelin Asp344 (M) 0.29
14 Leu348 (S) Embelin 4.94
15 Thr347 (M) Embelin 3.26
16 Embelin Asp313 (S) 0.10
17 His409 (S) Embelin 41.56
18 Met345 (S) Embelin 0.10
19 Embelin Met345 (S) 0.14
20 Embelin Ile438 (M) 0.05
21 Val314 (S) Embelin 0.10
22 Embelin Val314 (S) 0.10
23 Embelin Met345 (M) 5.90
24 Embelin His405 (S) 0.14
25 Pro437 (S) Embelin 6.14
26 Embelin Leu348 (M) 0.77
27 Embelin Leu348 (S) 0.43
28 Embelin His409 (S) 0.05
29 Embelin Tyr436 (S) 0.34
30 Tyr436 (S) Embelin 0.05
31 Embelin Tyr390 (S) 0.24
32 Embelin Pro437 (S) 0.05
33 Tyr390 (S) Embelin 0.05
34 Embelin Thr347 (M) 0.05
(M) Main chain, (S) Side Chain. The residues in bold format are the ones that were
involved in H-bond formation in the representative average structure of TACE-
embelin complex, obtained subsequent to molecular dynamics simulations.
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that this bond was lost when the energetically favored
conformation achieved by the docked complex. Multiple
hydrophobic and van der Waals interactions further
stabilized the binding of embelin to TACE. The residues
which participated in these interactions included Met 345,
Gly 346, Thr 347, His 405, His 415, Pro 437 and Ile 438.
Figure 2C shows shift in orientation of the ligand withinthe catalytic cleft of TACE after attaining a stable state.
The position of the docked ligand changed significantly
during MD simulation. This shift was monitored in
reference to the stoichiometry obtained after molecular
docking.
Embelin-treated breast cancer cells showed reduction in
TACE and inhibition of cancer cell growth and metastasis
In order to validate the molecular dynamics results of
docking embelin to TACE, we performed experiments
using two human breast cancer cell lines, MCF7 and
MDA-MB-231. Cells treated with embelin showed decline
in their viability with IC50 dose of 15–20 μM. We next
treated the cells with 15 μM embelin for 48 h and exam-
ined their TACE expression level by western blotting and
immunostaining. As shown in Figure 3A and B, embelin-
treated cells showed statistically significant (p < 0.01)
decrease in TACE expression in multiple independent
experiments. Similar results were seen in immunostaining
of TACE in control and embelin-treated cells. Further-
more, the activity of TACE, as quantitated by measuring
the TACE-dependent fluorescence released by quenched
QXLTM520/5-FAM FRET substrate (Sensolyte, Anaspec
Inc., CA), decreased (~50%) in cells treated with 20 μΜ of
embelin (Figure 3C). Consistent with this, the level of
TNF-α, a downstream effector of TACE, also decreased
(4-fold) in embelin-treated cells as compared to the un-
treated controls (Figure 3D). We also performed RT-PCR
analysis in control and embelin-treated cells for down-
stream effectors of TACE, including TNF-α, TGF-α,
AREG, Akt, Erk-2, ULBP-2 and CD163. Whereas no dif-
ference was observed in TNF-α, TGF-α and AREG; there
was an increase in Akt, ERK-2 and ULBP-2, and decrease
in CD163 (Figure 3E).
We have earlier reported that the overexpression of
mortalin/mtHsp70 in cancer cells contributes to their
malignant properties, including increased colony forming
efficacy, migration and invasion [27,28]. In order to inves-
tigate the effect of embelin on cancer cell metastasis,
we next generated mortalin-overexpressing metastatic
derivatives of MCF7 and MDA-MB-231 cells. Expression
of myc-tagged exogenous expression of mortalin was
confirmed by western blotting with anti-myc tag anti-
body (Figure 4A). Morphological observation of cells in
either control or embelin-supplemented medium revealed
their growth arrest in the latter (Figure 4B). As shown in
Figure 4C, we found that the embelin was cytotoxic to
both MCF7 and MDA-MB-231 cells, and their metastatic
derivatives in equivalent doses (15 μM), suggesting its
potency for the treatment of metastatic cancers. Embelin
caused significant reduction in colony forming efficacy
(CFE); 80% and 40% reduction in MCF7 cells and its
metastatic derivatives, respectively. Embelin-treated MDA-
MB-231 cells revealed about 90% reduction in CFE in
Figure 3 Effects of embelin on TACE expression and activities. (A) Expression of TACE in control and embelin (15 μM)-treated MCF7 cells
as detected by western blotting. Actin was used as an internal control. (B) Immunostaining of TACE in control and embelin-treated MCF-7 cells.
(C) TACE activity in control and embelin-treated cells; TACE inhibitor, TAPI-0 (10 μM), was used as a control. (D) TNF-α expression in control and
embelin-treated cells. (E) RT-PCR analysis of TACE-effectors showing no change in TNF-α, TGF-α and ARFG (upper panel); Akt, Erk-2 and ULBP-2
showed increase, and CD163 showed decrease in embelin-treated cells.
Figure 4 Effects of embelin on proliferation and migration of breast cancer cells. (A) Expression of mortalin in mortalin-myc transduced
metastatic cells detected by western blotting with anti-myc and anti-mortalin antibodies. (B) Morphology of embelin-treated control and
mortalin-overexpressing metastatic cells indicative of growth arrest. (C) Viability of human breast cancer cells (MCF7 and MDA-MB-231) and their
mortalin-overexpressing derivatives. The 4-parameter logistic curve is plotted using Prism 6 software (GraphPad Software, Inc., CA). (D) Colony
forming efficacy and quantitation (E) from three independent experiments is shown. ***p < 0.001.
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(Figure 4D and E) supporting that embelin could be a
potent drug to treat metastatic cancers.
In order to evaluate the effect of embelin on cancer
metastasis, we performed cell migration and wound scratch
assays in control and embelin-treated cells under the
conditions (15 μM embelin treatment for 10–20 h) when
their growth, per se, was not affected. We found that
the invasion of both MCF7 and MDA-MB-231 cells
through matrigel was inhibited in embelin-treated cultures
(Figure 5A and B; quantitation) under the conditions
when the cell number was not altered (data not shown).
Visual examination of cell migration by wound-scratch
assays also revealed slower migration of cells in the wound
area in MCF-7 and MDA-MB-231 cells (Figure 5C and
D). In light of this data, we next examined the expression
of metastatic markers including MMP-2, MMP-9 and
VEGF in control and treated cells and found reduction
(60%, 25% and 48%, respectively) in their level of expres-
sion (Figure 6A). We, next, examined the expression
status of an upstream regulator, hnRNP-K that has been
shown to play critical role in cell migration. We found
that in response to embelin treatment there was a signifi-
cant reduction in hnRNP-K (Figure 6A and B), supporting
its potency for treatment of metastatic cancer.
Discussion
In the present study, we investigated the molecular
mechanism of the effect of embelin on TACE and cancer
cell characteristics. We found that embelin docks into
the active site of TACE that contains zinc atom coordinatedFigure 5 Effects of Embelin on invasion capacity of breast cancer ce
(B) Quantitation from three independent experiments showing 20-30% decre
of the control and embelin-treated cells. (D) Quantitation from three indepen
cells. *p < 0.05 and **p <0.01.by a conserved zinc binding motif (405-HexGHxxGxxH-
415) [15] as shown by the analysis of three dimensional
structure of TACE by Q-site Finder server. Apart from this
conserved motif, the binding pocket also had Lys 348 and
Gly 349, which are considered to be important for the
activity of this enzyme [31]. The predicted pocket also
coincided with the binding site of the ligand present in
the co-crystallized structure obtained from PDB (1BKC).
The docking score of 3D structure of embelin with the
above mentioned active site of TACE was −9.06 suggest-
ing high binding affinity of embelin for TACE. It showed
molecular interactions with histidine and glutamate
residues, which play an important role during the proteo-
lytic reaction process. Furthermore, embelin also showed
bonding with the zinc atom. Taken together, these interac-
tions of embelin and TACE were expected to interfere
with the interaction of substrate to the active site of
TACE, hence consolidating the idea of embelin as TACE
inhibitor.
The dynamics of the docked complex were then studied
to analyze its stability inside the bodily conditions. A
simulation length of 10 ns was used in the study to allow
rearrangement of the ligand bound protein molecule to
find its stable binding mode. The RMSD trajectory was
analyzed to comment on the stability of the docked com-
plex. The curve did not deviate much after 6 ns, which
indicated that the complex has reached its energetically
favored conformation. A structure representing the most
stable time frame was used to examine the molecular
interaction pattern in the ligand bound protein complex.
Various non-covalent interactions including H-bonds,lls. (A) Cell invasion assay in control and embelin-treated cells.
ase in invasion capacity; *p < 0.05 and **p < 0.01. (C) Wound-scratch assay
dent experiments showing 20-30% decrease in the migration capacity of
Figure 6 Effects of embelin on metastasis-mediating proteins. Western blot analyses of proteins involved in cancer cell migration. (A) MMP-2,
MMP-9, VEGF and hnRNP-K decrease in embelin-treated MCF-7 cells. The pixel calculation of western blots by actin normalization was done using
ImageJ software (NIH, MA). (B) Decrease in the expression of hnRNP-K, as detected by immunostaining. (C) Schematic representation of possible action
of embelin on cancer cell metastasis as based on the present study.
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responsible for the stable interaction of embelin withTACE.
The ringed structure of embelin occupied the same groove
over the entire simulation run, whereas the long hydropho-
bic tail found a new groove for itself. Some new residues
were interacting with embelin because of this shift in the
position of the tail region. The dynamic stability of ligand
during majority of the simulation time and its interactions
with active site key residues of the enzyme plausibly con-
clude the mode of action of embelin on inhibition of TACE
and it’s well known anti-inflammatory activity.
We next investigated the effect of embelin on TACE
expression level in breast cancer cell lines. The data
revealed decrease in TACE and growth arrest of cancer
cells in response to embelin treatment. TACE processes
precursor TNF-α to its bioactive 17-kDa protein with
high specificity and efficacy [32]. The latter is not only
an important mediator of inflammatory phase of wound
healing, but also a key regulator matrix re-modeling,
angiogenesis and tumor metastasis. Embelin-treated cells
showed suppression of TACE activity, supported by ana-
lysis of downstream effectors of TACE. Consistent with
other reports, TACE inhibition was endorsed by transcrip-
tional activation of Akt [33,34], Erk-2 [35] and ULBP-2 [36]
and repression of CD163 [37]. On the other hand, level of
expression of TNF-α, TGF-α and AREG transcripts did not
show any difference in control and embelin-treated cells,
suggesting that the inhibition of TACE in response to thetreatment with embelin may operate at protein level and
the increase in Akt and Erk-2 represent adaptive feedback
response of cells [33-38].
Tumor microenvironment, tumor-associated macro-
phages and cytokines in particular, have been established
to play key role in progression, metastatic spread of breast
cancer and angiogenesis that are indeed the major cause
of therapeutic failure. Macrophages are activated by cyto-
kines to secrete angiogenic factors including vascular
endothelial growth factor (VEGF) that contribute to
cancer cell aggressiveness. Since the release of cytokines
from tumor cells is mediated by their ectodomain shed-
ding by TACE, specific inhibitors of TACE have been in
clinical trials as therapeutic drugs for aggressive and
advanced metastatic cancers. Based on our above findings
on the targeting and inhibition of TACE by embelin, we
investigated whether embelin could inhibit metastasis
of breast cancer cells. Consistent with our prediction,
metastatic derivatives of the cell lines, generated by morta-
lin overexpression, were also found to undergo growth
arrest and decrease in the malignant characteristics
including cell migration and invasion in the presence of
embelin. As shown in the schematic diagram in Figure 6C,
TNF-α has been shown to stimulate synthesis and secre-
tion of active MMPs [33]. We found that MMP-2 and
MMP-9 were significantly decreased in embelin-treated
cells suggesting its anti-metastasis potential. Furthermore,
upstream regulators of MMPs, hnRNP-K and VEGF
Dhanjal et al. BMC Cancer 2014, 14:775 Page 11 of 12
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cells suggesting that embelin might block multiple cancer
cell metastasis signaling pathways (Figure 6C). Although
the molecular intricacies of these regulations warrant
further studies, the present study provided evidence
that the anti-inflammatory and anti-metastasis activities
of embelin may be mediated by its binding to TACE.
Conclusion
Molecular docking and experimental data demonstrated
that embelin is a potential inhibitor of TACE. Furthermore,
it inhibited malignant properties of breast cancer cells
through inactivation of metastatic signaling molecules
including MMPs, VEGF and hnRNP-K, and hence pro-
posed it as a natural anticancer drug.
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